Introduction
Nucleoside antimetabolites, such as 1-β-D-arabinofuranosylcytosine (araC), 2-chloro-2'-deoxyadenosine (CldA), 9-β-D-arabinofuranosyl-2-fluoroadenine monophosphate (fludarabine, FaraAMP) and 2'-deoxy-2',2'-difluorocytidine (gemcitabine, dFdC) ( Fig. 1) , have been widely used as not only antileukemic agents but also antitumor agents against solid tumors.
(2'S)-2'-Deoxy-2'-C-methylcytidine (SMDC)
We have synthesized (2'S)-2'-deoxy-2'-C-methylcytidine (SMDC), (2'R)-2'-deoxy-2'-C-methylcytidine (RMDC), and (2'S)-2'-deoxy-2'-C-ethylcytidine (SEDC) from uridine to elucidate the steric requirement of the substituent at the 2'β-position of 2'-deoxycytidine. 29) Against mouse L1210 cells in vitro, SMDC was as potent as araC (Table   I ) but RMDC was 150-fold less effective than SMDC, and SECD was not effective up to 100 μg/mL. Additionally, 2'-deoxy-2'-(methylthio)-β-D-arabinofuranosylcytosine did not show any cytotoxicity toward L5178Y cells in vitro up to 100 μg/mL. Therefore, it appears that increasing bulkiness of the 2'-substituent in 2'-deoxycytidine greatly reduces cytotoxicity.
SMDC is a relatively good substrate of dCK (Table III) 52) and a very poor substrate of CDA. Chemically synthesized 5'-triphosphate (SMDCTP) is potent competitive inhibitors of dCTP against DNA polymerase α, β, and γ with Ki values of 0.05, 0.10, and 0.07 μM, respectively (Table IV) . These values indicate that SMDCTP binds to DNA polymerase α , β , and γ 25-, 39-, and 11-fold better than the natural substrate dCTP. 32) Although these data were promising SMDC to be effective in vivo, SMDC showed only marginal activity against a mouse leukemic P388 model with T/C values of 111% at 30 mg/kg/day and 126% at 100 mg/kg/day treatments, while araC showed good activity with those of 184% at 10 mg/kg/day and 189% at 30 mg/kg/day.
On the basis of these data, SMDCMP (5'-monophosphate) and/or SMDCDP (5'-diphosphate) would not be good substrates for CMP/UMP kinase and/or NDP kinase to produce the active nucleotide, SMDCTP, which is potent inhibitors of several DNA polymerases. Although the structural basis of this drawbacks is not clear enough, the precedent example of this type is 3'-azido-3'-deoxythymidine (AZT) 5'-monophosphate (AZTMP), which is not a good substrate of TMP kinase, although AZT is a good substrate of TK1. 1) Previously, we believed that nucleoside kinases have most strict substrate specificity among various nucleoside and nucleotide kinases. However, now, we know that a nucleoside 5'-monophosphate kinase might also have rather strict substrate specificity.
1-(2-Deoxy-2-methylene-β -D-erythro-pentofuranosyl)cytosine (DMDC)
DMDC has an allylic alcohol system together with the 3'-secondary alcohol in the sugar moiety. This allylic alcohol in DMDC could be stable at a nucleoside level, but if it is phosphorylated to the 5'-polyphosphates by cellular kinases, the following chemical reactivities are expected. (i) At the 5'-diphosphate level (DMDCDP), it could be a mechanism-based inhibitor of ribonucleotide reductase if a 3'-radical is formed by its enzyme action.
(ii) When its 5'-triphosphate (DMDCTP), although this could be an inhibitor of DNA polymerases, is incorporated into DNA molecules, the allylic alcohol becomes a more reactive allyl phosphate ester to be cleaved by nucleophiles.
In vitro cytotoxicity of DMDC against various human tumor cell lines including mouse leukemic L1210 cells is shown in Table I . 30, 40) Cytotoxicity spectrum of DMDC is quite similar to that of 5-FU, but not to those of SMDC and araC. Unlike araC, DMDC was not a substrate of CDA from mouse kidney. Together with these characteristics, chemically synthesized DMDCTP was a potent inhibitor of DNA polymerase α, β, and γ with K i values of 0.42, 2.52, and 1.00 μM, respectively, in a manner competitive with dCTP, while araCTP inhibited only DNA polymerase α with a K i of 1.10 μM.
32) It was also found that DMDCTP was incorporated into DNA molecules at the site complementary to guanine by the action of DNA polymerase α using a synthetic template-primer system. In this experiment, DMDCTP apparently acted as a chain-terminator, but whether it was a real chain-terminator or a result of strand-break after a further elongation of the chain, which we postulated, has not been proved yet. Moreover, DMDCDP was reported to be a time-dependent inhibitor of E. coli RDR, 8) while it did not inhibit RDR in L1210 murine leukemia and LX-1 human lung carcinoma cells.
24)
In vivo antileukemic activity of DMDC was also examined by using female CD2F 1 mice bearing ip inoculated L1210 cells. DMDC administered i.p. once a day for 5 days at 250 mg/kg had a T/C (%) of 235.
54) The activity of DMDC was schedule-dependent with much more therapeutic effect obtained by daily treatment than by a single treatment. DMDC was also effective against colon 26 murine carcinoma, M5076 murine reticulum cell sarcoma, LX-1 human lung cancer xenograft, and SK-Mel-28 human melanoma xenograft, which are less sensitive or refractory to araC. The efficacy of DMDC correlates well with tumor the levels of CDA activity in human tumor xenograft models. 11, 36) DMDC was highly effective in tumors with higher levels of CDA activity, whereas lower levels yielded only slight antitumor activity. In contrast, gemcitabine is only slightly effective in tumors with higher levels of the enzyme. The activation of DMDC to DMDCMP by dCK would be competitively inhibited by endogenous dCyd in cells. Therefore, the dCyd concentration in tumor cells, that is regulated by CDA, would be critical for phosphorylation of DMDC. On the other hand, since gemcitabine is a good substrate of CDA, in tumors with higher levels of CDA, both dCyd and gemcitabine are deaminated to be uracil derivatives before phosphorylation.
Phase I clinical studies using DMDC with i.v. administration against solid tumors had already been carried out in Japan.
15) The major dose-limiting toxicity was hematological depression, particularly leukopenia and neutropenia. The maximum tolerated dose for the 5-consecutive-day administration was 40 mg/m 2 . Furthermore, phase I clinical trial with p.o.
administration was also carried out.
28) The dose-limiting toxicities were anorexia, leukopenia, thrombocytopenia, and anemia. General fatigue was the common nonhematological toxicity.
The maximum-tolerated dose was 18 mg/m 2 /day. At the 18-mg/m 2 /day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), the area under the plasma drug concentration-time curve on day 1 were 1.7496 h, 112.9 ng/mL, and 399.8 ng x h/mL, respectively. Forty to 50% of the administered dose was recovered in the urine, indicating its good bioavailability and resulting significant systemic exposure to the drug, which may enable chronic oral treatment. Details of the clinical pharmacokinetics were also reported.
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All-trans retinoic acid (ATRA) differentiation therapy against acute promyelocytic leukemia (APL) greatly improved its prognosis. However, although complete remission can be achieved with ATRA alone, disease-free survival is still too short due to relapse. DMDC was found both to inhibit the growth and to induce differentiation of APL cell lines. ATRA combined treatment with DMDC induced differentiation of leukemia cells that had been freshly isolated from APL patients.
38)

1-(2-C-Cyano-2-deoxy-1-β-D-arabino-pentofuranosyl)cytosine (CNDAC)
Introduction of an electron-withdrawing group (EWG) into the 2'β position would increase the acidity of the 2'α proton. If such a nucleoside is incorporated into DNA after its enzymatic phosphorylation, the EWG becomes β to the phosphate diester in the DNA. In this case, β-elimination should produce (i) DNA strand-breaks or (ii) abasic site formation as illustrated in Fig. 2 . Since strand-breaks in DNA by radiation therapy have been hypothesized to produce tumor cell death, it is worth examining whether the nucleoside having such chemical reactivities inhibits tumor cell growth or not. As an example of the nucleoside that has an EWG at the 2'β position of 2'-deoxycytidine, we synthesized
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In vitro cytotoxicity of CNDAC against various human tumor cell lines was compared with araC and DMDC and is summarized in Table II . Although cytotoxicity spectrum of CNDAC is quite different from that of araC, the potency of CNDAC seemed not to be better than that of DMDC. In vivo antileukemic activity of CNDAC was compared with araC against i.p.-implanted P388 in CDF 1 mice. CNDAC administered i.p. 10 consecutive days at a dose of 20 mg/kg had a T/C of more than 600%, and 5 out of 6 mice survived more than 60 days, while araC on the same schedule showed a T/C of only 225%. CNDAC was phosphorylated to CNDACMP by dCK, but its relative activity was just a half of the phosphorylation of 2'-deoxycytidine with about 5-fold larger Km value (Table III) . 51, 52) Further phosphorylation of CNDACMP to its 5'-triphosphate (CNDACTP) was essential for its antitumor activity. 18) Unlike araCTP, CNDACTP would not act as a feedback inhibitor of dCK, because its accumulation in cells was in a concentration-dependent manner over a 1000-fold range of CNDAC concentrations. On the other hand, CNDAC was a poor substrate of CDA from mouse kidney with 4.2% of the relative activity (Table III) .
CNDACTP inhibited DNA polymerase α with a Ki value of 0.16 μM in a competitive manner with dCTP, the Ki value of which is about 7-fold more potent than that of araCTP (Table IV) . In vitro DNA primer extension experiments demonstrated that CNDACMP was incorporated into the C site of the elongating DNA strand, and seemed to cause termination of the primer DNA elongation at the site of the analog incorporation. CNDACTP was an effective substrate for DNA polymerase α, which exhibited a substrate efficiency that was similar to that for dCTP incorporation. After incorporation of CNDACMP in a DNA strand, further elongation was rather slow process, because of its steric effect. However, once a nucleotide was elongated next to CNDACMP, β-elimination occurred to give 2'-C-cyano-2',3'-didehydro-2',3'-dideoxycytidine (ddCNC) at the 3'-terminus as our hypothesis. 6, 18, 33) This β-elimination reaction was confirmed not only in an enzyme level but also in a tumor cell level. Since DNA replication in intact cells is much more complex than the simple in vitro model we have used, it is interesting to examine whether such the chemical reaction actually occurs in vivo. Moreover, CNDACTP inhibited T7 RNA polymerase with a Ki value of 0.25 mM, while a Km value of CTP was 0.45 mM. Using whole cells, it was detected that CNDAC also inhibited RNA synthesis. 7) However, the mechanism of this action in detail and contribution to its antitumor activity are in future studies.
The ability of CNDAC to induce DNA strand breaks by a β-elimination-mediated mechanism after its incorporation into the DNA strand is a novel mechanism. This unique strand-breaking action seems to be the basis of its ability to induce cell cycle arrest at the G 2 phase, as distinct from the S phase block seen in the cells treated with araC and gemcitabine.
Since certain DNA-damaging agents such as ionizing radiation and cisplatin are know to block the cell cycle at the G 2 phase, it is logical to speculate that the β-elimination-mediated DNA strand breaks caused by CNDAC might activate similar signaling pathways.
6, 7)
Since CNDAC is a weak substrate of CDA, which is a major inactivating enzyme and 
1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd)
Tumor cells are well known to be heterogeneous. In this respect, the cell cycle of certain tumor tissues is not synchronized. If certain antitumor agent has a mechanism of action inhibiting only DNA synthesis, such the agent only acts in S phase of the cell cycle.
Although solid tumor cells grow more rapidly than normal cells, their growth rate is much slower than blood cells. Therefore, such the antitumor agent can kill only a part of the tumor cells. Inhibition of DNA synthesis is the most prominent activity of CNDAC. However, CNDAC also inhibits RNA synthesis in some extent depending on cells used and this effect on RNA synthesis may also contribute to its cytotoxicity, particularly in more indolent cell populations in which RNA synthesis would take on more importance. Therefore, we have been looking for a nucleoside antimetabolite, which inhibits both DNA and RNA syntheses.
We designed 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (ECyd), from which we expected that ECyd 5'-diphosphate (ECDP) would inhibit ribonucleotide reductase and ECyd 5'-triphosphate (ECTP) would inhibit RNA polymerase to cause both DNA and RNA synthesis inhibition. 5, 19, 20, 35, 45, 46) ECyd showed potent cytotoxicity in vitro against various human tumor cell lines with nanomoler to subnanomoler levels of the IC 50 values. Cytotoxic spectrum of ECyd was somewhat different from those of three DNA synthesis inhibitors, araC, DMDC and CNDAC (Table II) . ECyd exhibited strong antitumor activity against various human xenographts implanted into nude mice and nude rats via i.v. administration. Its antitumor potency was rather schedule independent and did not produce severe toxicities such as diarrhea, myelosuppression or loss in body weight. Initially, ECDP was anticipated to inhibit ribonucleotide reductase, but it did not inhibt the enzyme from E. coli even at mM concentrations.
Since UCK activity in human tumor tissues is well known to be relatively high compared to its activity in normal tissues, tumor selective cytotoxicity of ECyd could therefore be expected clinically. Recently, a UCK family consisting of two members, UCK1
and UCK2, has been reported in human cells. 25, 53) Therefore, to determine which isozyme is responsible to the phosphorylation of ECyd is important for further development. We investigated the relations between expression of UCK1 and UCK2 at both mRNA and protein levels, and ECyd phosphorylation activity in a panel of 10 human tumor cell lines.
44) The UCK activity was found to be well correlated with the cells' sensitivity to ECyd. Furthermore, the mRNA or protein expression level of UCK2 was closely correlated with UCK activity in these cell lines, but neither the level of expression of UCK1 mRNA nor that of protein was correlated with the enzyme activity. Comparison of the protein expression level of UCK2 in several human tumor tissues and the corresponding normal tissues exhibited that the expression of UCK2 protein was barely detectable in 4 out of the 5 human tissues, but tended to be high in the pancreatic tumor tissue. In any of the normal tissues, the expression could not be detected at all. Therefore, expression of UCK2 seemed to be correlated with cellular sensitivity to ECyd, and it may contribute to the tumor-selective cytotoxicity of ECyd. ECyd is now under phase I clinical study against solid tumors in U. S. A.
Conclusion
Since the great success of gemcitabine for the treatment of solid tumors in patients has been achieved with a combination of other antitumor agents or radiation therapy, the concept of a nucleoside antimetabolite, although it is the old idea, has been revived to further Table I . The reaction mixture containing 100 mM Tris-HCl buffer (pH 7.5), 50 μM each analog, 0.5 mM UTP, 2.4 mM MgCl 2 , 1 mg/mL BSA, 0.5 mM DTT, 1 mM NaF, 1 mM tetrahydrouridine, and the enzyme in a total volume of 40 μL was incubated at 37 °C for 15 min, followed by HPLC analysis at 280 nm. Each phosphorylation was confirmed by conversion of the product to the substrate by alkaline phophatase, after incubation overnight. b The reaction mixture containing 100 mM Tris-HCl buffer (pH 7.5), 0.05-1.0 mM of the substrate, 2.4 mM MgCl 2 , 1 mg/mL BSA, 0.5 mM DTT, and the enzyme in a total volume of 40 μL was incubated at MgCl 2 , and an aliquot of the reaction mixture. In the case of DNA polymerase β, potassium phosphate was replaced by 40 mM Tris-HCl (pH 8.5). In the case of DNA polymerase γ, 200 mM KCl was added to the mixture for the assay. For kinetic analysis, the concentration of the inhibitor and dCTP were varied. After incubation, the reaction mixture was chilled in an ice bath and 20 μL was transferred to DEAE-cellulose paper disc.
The discs were washed with 5% Na 2 HPO 4 (x 6), H 2 O (x 1), EtOH (x 2) and ether, and dried. The remaining radioactivity was measured in a scintillation liquid. H 
